Zymeworks Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ZYME | ZBIO | ZLAB | XNCR | IMTX | ZURA | |
|---|---|---|---|---|---|---|
| Market cap | 2.22B | 1.85B | 2.83B | 2.60B | 1.05B | 387.23M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | 25.5 | -6.1 | -10.9 | -9.9 | -3.4 | -5.9 |
| Price/book | 27.5 | 7.3 | 4.2 | 4.0 | 2.1 | 2.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +72.85% | −12.32% | −1.51% | +150.21% | −25.14% | +15.52% |
| Today | +2.69% | +0.28% | +3.83% | +14.33% | −2.33% | +0.75% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ZYME news ›Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma, BeiGene, Zymeworks, ALX Oncology
Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing openPR.com Gastric Cancer Market to Expand Rapidly by 2035 Amid Increasing Investments and Innovation | AstraZeneca, Daiichi Sankyo, Bristol-Myers Squibb, Amgen, Jazz Pharma,…
Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination
Special meeting of Impact Biomedical stockholders to approve the proposed Business Combination scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time Upon closing, the combined company is expected to operate as Zoar Limited…
Zymeworks (ZYME) Projected to Post Quarterly Earnings on Monday
Posted by Tristan Rich on Nov 2nd, 2026 Zymeworks stock opened at $28.61 on Monday. The firm has a market capitalization of $2.02 billion, a P/E ratio of -14.16 and a beta of 1.17. The firm has a fifty day moving average of $27.30 and a…
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates - Slideshow
2026-10-29. The following slide deck was published by Zymeworks Inc. The following slide deck was published by Zymeworks Inc. in conjunction with this event.
Zomedica Announces "Fourth Friday at Four" Webinar on October 23, 2026: Zomedica's Clinical Program: How Evidence Drives Adoption
ANN ARBOR, MI / ACCESS Newswire / October 8, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion…
Zymeworks (NASDAQ:ZYME) versus Coherus Oncology (NASDAQ:CHRS) Financial Review
Posted by Mitch Edgeman on Oct 28th, 2026 Zymeworks (NASDAQ:ZYME – Get Free Report) and Coherus Oncology (NASDAQ:CHRS – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based…
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Posted by Sarita Garza on Oct 27th, 2026 Adam Schayowitz, Zymeworks’ head of R&D, said Roche is expected to fund research and development for ZW209, including the Phase 1a study, while Zymeworks will conduct the initial global trial. Roche…
Roche bets up to $813M on Zymeworks lung cancer candidate
Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for $55 million upfront and up to $758 million more in conditional payments, plus royalties on future sales. The…
More from 1 other outlet
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
As of Sep 23, 2026 4:44 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of the Phase 1b trial,…
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Among response-evaluable patients with high-grade serous PROC, ZW191 demonstrated a cORR of 64.5% at 6.4 mg/kg and 55.3% at 9.6 mg/kg, with disease control rates of 100% and 92.1%, respectively. These findings demonstrate compelling…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com14
- stocktitan.net7
- themarketsdaily.com6
- seekingalpha.com3
- businessupturn.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 67 articles, not a forecast.